Literature DB >> 24778160

Pathogen-driven cancers and emerging immune therapeutic strategies.

Natalie Vandeven1, Paul Nghiem.   

Abstract

Infectious agents play an etiologic role in approximately 20% of cancer cases worldwide. Eleven pathogens (seven viruses, three parasites, and one bacterium) are known to contribute to oncogenesis either directly via the expression of their protein products or indirectly via chronic inflammation. Although prevention of infection and antimicrobial treatments have helped in reducing infection rates and the incidence of associated malignancies, therapies for these cancers remain limited. The importance of immune control over malignant progression is highlighted by the fact that many cancers, particularly those induced by pathogens, occur more frequently among immunosuppressed patients as compared with healthy individuals. Therefore, therapeutic strategies that can elicit a robust immune response and restore tumor detection may be a beneficial approach for treating these cancers. In addition, the study of immune escape mechanisms used by pathogens and their associated cancers may provide insight into the mechanisms of malignant transformation and improved therapies for cancer more generally. ©2014 AACR.

Entities:  

Mesh:

Year:  2014        PMID: 24778160      PMCID: PMC4135058          DOI: 10.1158/2326-6066.CIR-13-0179

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  44 in total

Review 1.  The interplay between Epstein-Barr virus and the immune system: a rationale for adoptive cell therapy of EBV-related disorders.

Authors:  Anna Merlo; Riccardo Turrini; Riccardo Dolcetti; Debora Martorelli; Elena Muraro; Patrizia Comoli; Antonio Rosato
Journal:  Haematologica       Date:  2010-04-26       Impact factor: 9.941

2.  Does antiviral therapy for hepatitis B and C prevent hepatocellular carcinoma?

Authors:  Anna Suk-Fong Lok
Journal:  J Gastroenterol Hepatol       Date:  2011-02       Impact factor: 4.029

3.  Prevalence of HPV types in cervical specimens from an integrated healthcare delivery system: baseline assessment to measure HPV vaccine impact.

Authors:  Eileen F Dunne; Nicola P Klein; Allison L Naleway; Roger Baxter; Sheila Weinmann; Karen Riedlinger; Barbara Fetterman; Martin Steinau; Mariela Z Scarbrough; Julianne Gee; Lauri E Markowitz; Elizabeth R Unger
Journal:  Cancer Causes Control       Date:  2013-01-05       Impact factor: 2.506

Review 4.  Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors.

Authors:  Giulia Mesiano; Maja Todorovic; Loretta Gammaitoni; Valeria Leuci; Lidia Giraudo Diego; Fabrizio Carnevale-Schianca; Franca Fagioli; Wanda Piacibello; Massimo Aglietta; Dario Sangiolo
Journal:  Expert Opin Biol Ther       Date:  2012-04-14       Impact factor: 4.388

Review 5.  Immunotherapy for cervical cancer: Research status and clinical potential.

Authors:  Jun-Han Su; Anjui Wu; Elizabeth Scotney; Barbara Ma; Archana Monie; Chien-Fu Hung; T-C Wu
Journal:  BioDrugs       Date:  2010-04-01       Impact factor: 5.807

Review 6.  The prevention of infection-associated cancers.

Authors:  Silvio De Flora; Paolo Bonanni
Journal:  Carcinogenesis       Date:  2011-03-24       Impact factor: 4.944

7.  Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma.

Authors:  Adil I Daud; Ronald C DeConti; Stephanie Andrews; Patricia Urbas; Adam I Riker; Vernon K Sondak; Pamela N Munster; Daniel M Sullivan; Kenneth E Ugen; Jane L Messina; Richard Heller
Journal:  J Clin Oncol       Date:  2008-11-24       Impact factor: 44.544

Review 8.  Global burden of cancers attributable to infections in 2008: a review and synthetic analysis.

Authors:  Catherine de Martel; Jacques Ferlay; Silvia Franceschi; Jérôme Vignat; Freddie Bray; David Forman; Martyn Plummer
Journal:  Lancet Oncol       Date:  2012-05-09       Impact factor: 41.316

9.  Using antimicrobial adjuvant therapy in cancer treatment: a review.

Authors:  Kenneth Alibek; Aliya Bekmurzayeva; Assel Mussabekova; Bolat Sultankulov
Journal:  Infect Agent Cancer       Date:  2012-11-20       Impact factor: 2.965

10.  Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy.

Authors:  Eric A Reits; James W Hodge; Carla A Herberts; Tom A Groothuis; Mala Chakraborty; Elizabeth K Wansley; Kevin Camphausen; Rosalie M Luiten; Arnold H de Ru; Joost Neijssen; Alexander Griekspoor; Elly Mesman; Frank A Verreck; Hergen Spits; Jeffrey Schlom; Peter van Veelen; Jacques J Neefjes
Journal:  J Exp Med       Date:  2006-04-24       Impact factor: 14.307

View more
  17 in total

Review 1.  Oncogenic Epstein-Barr virus recruits Nm23-H1 to regulate chromatin modifiers.

Authors:  Saurabh Pandey; Erle S Robertson
Journal:  Lab Invest       Date:  2017-10-16       Impact factor: 5.662

Review 2.  Infection and immune control of human oncogenic γ-herpesviruses in humanized mice.

Authors:  Donal McHugh; Nicole Caduff; Anita Murer; Christine Engelmann; Yun Deng; Hana Zdimerova; Kyra Zens; Obinna Chijioke; Christian Münz
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2019-05-27       Impact factor: 6.237

Review 3.  Complex Role of Microbiome in Pancreatic Tumorigenesis: Potential Therapeutic Implications.

Authors:  Suneetha Amara; Li V Yang; Venkataswarup Tiriveedhi; Mahvish Muzaffar
Journal:  Cells       Date:  2022-06-11       Impact factor: 7.666

Review 4.  Therapeutic cancer vaccines.

Authors:  Cornelis J M Melief; Thorbald van Hall; Ramon Arens; Ferry Ossendorp; Sjoerd H van der Burg
Journal:  J Clin Invest       Date:  2015-07-27       Impact factor: 14.808

5.  Genomic Characterization of Six Virus-Associated Cancers Identifies Changes in the Tumor Immune Microenvironment and Altered Genetic Programs.

Authors:  Frederick S Varn; Evelien Schaafsma; Yue Wang; Chao Cheng
Journal:  Cancer Res       Date:  2018-09-25       Impact factor: 12.701

Review 6.  Regulation of the metastasis suppressor Nm23-H1 by tumor viruses.

Authors:  Shuvomoy Banerjee; Hem Chandra Jha; Erle S Robertson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-09-10       Impact factor: 3.000

Review 7.  Cancer therapy in a microbial bottle: Uncorking the novel biology of the protozoan Toxoplasma gondii.

Authors:  Barbara A Fox; Kiah L Butler; Rebekah B Guevara; David J Bzik
Journal:  PLoS Pathog       Date:  2017-09-14       Impact factor: 6.823

Review 8.  Ancient oncogenesis, infection and human evolution.

Authors:  Riaan F Rifkin; Marnie Potgieter; Jean-Baptiste Ramond; Don A Cowan
Journal:  Evol Appl       Date:  2017-07-11       Impact factor: 5.183

Review 9.  Anti-PD-1/PD-L1 Blockade Immunotherapy Employed in Treating Hepatitis B Virus Infection-Related Advanced Hepatocellular Carcinoma: A Literature Review.

Authors:  Bin Li; Cong Yan; Jiamin Zhu; Xiaobing Chen; Qihan Fu; Hangyu Zhang; Zhou Tong; Lulu Liu; Yi Zheng; Peng Zhao; Weiqin Jiang; Weijia Fang
Journal:  Front Immunol       Date:  2020-05-28       Impact factor: 7.561

10.  Integrative metabolic and transcriptomic profiling of prostate cancer tissue containing reactive stroma.

Authors:  Maria K Andersen; Kjersti Rise; Guro F Giskeødegård; Elin Richardsen; Helena Bertilsson; Øystein Størkersen; Tone F Bathen; Morten Rye; May-Britt Tessem
Journal:  Sci Rep       Date:  2018-09-24       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.